Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 July 1997 | Volume 127 Issue 2 | Pages 167-168
An 18-year-old man was hospitalized with intense thirst, polyuria, polydypsia, and weight loss. The oral mucosa appeared slightly dry, and mild hepatosplenomegaly was present. The physical examination was otherwise unremarkable. Diabetes mellitus and insipidus were ruled out by laboratory tests and imaging of the head. Fever and pancytopenia, in the absence of signs of disease other than xerostomia, prompted us to take a biopsy specimen from the bone marrow. Lymphoblastic lymphoma was diagnosed, polychemotherapy produced complete remission, and xerostomia disappeared. Two relapses were heralded by xerostomia that disappeared after remission was obtained through salvage protocols. The patient died of aspergillotic pneumonia during drug-induced pancytopenia. His salivary glands were clinically and histologically (Figure 1, panel A) normal, and no antinuclear antibodies were present in his serum, thus excluding the Sjogren syndrome [1]. LETTER
Paraneoplastic Autoimmune Xerostomia
TO THE EDITOR:
|
To investigate the nonfortuitous relation between xerostomia and lymphoma, we looked for autoantibodies to the salivary glands in the patient's serum. Circulating autoantibodies against the ductal cells of monkey salivary glands were demonstrated by indirect immunofluorescence at each relapse and during the second remission (Figure 1, panel B). The presence of autoantibodies was shown by direct immunocytochemistry in the patient's parotid gland (Figure 1, panels C and D).
Autoantibodies directed against cellular antigens are present in patients with a malignant condition [2]. Although rarely pathogenic [3], autoantibodies can be considered markers of an impending tumor because they can precede the appearance of clinically detectable cancer [4, 5]. To our knowledge, paraneoplastic autoimmune xerostomia has never been reported. Although the cellular target of these autoantibodies is unknown, we hypothesize that they might play a pathogenic role inhibiting salivary secretion.
We suggest that the sudden appearance of xerostomia together with autoantibodies to the salivary glands-after exclusion of the Sjogren syndrome, direct infiltration of the salivary glands by neoplasia, and primary disorders of water balance-should prompt a careful search for occult cancer.
Author and Article Information
|
|---|
|
|
|---|
References
|
|---|
|
|
|---|
1. Moutsopolous HM. Sjogren's syndrome. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's Principles of Internal Medicine. 13th ed. New York: McGraw-Hill; 1994:1661-4.
2. Agarwala SS. Paraneoplastic syndromes. Med Clin North Am. 1996; 80:173-84.
3. Lennon VA, Lambert EH. Autoantibodies bind solubilized calcium channel-omega conotoxin complexes from small cell lung carcinoma: a diagnostic aid for Lambert-Eaton myastenic syndrome. Mayo Clin Proc. 1989; 64:1498-553.
4. Posner JB. Parancoplastic syndromes. Neurol Clin. 1991; 9:919-36.
5. Folli F, Solimena M, Cofiell R, Austoni M, Tallini G, Fassetta G, et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer, N Engl J Med. 1993; 328:546-51.
About Letters
|
|
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
Include no more than 300 words of text, three authors, and five references
Type with double-spacing
Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||